Immunotherapy duo shows promise in rare cancer trial
NCT ID NCT04095208
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 22 times
Summary
This study tested a combination of two immunotherapy drugs, nivolumab and relatlimab, in 68 adults with advanced soft-tissue sarcoma. The goal was to see if the combo could shrink tumors or stop them from growing for at least 6 months. Participants had a specific immune feature in their tumors called tertiary lymphoid structures. The trial was completed, and results will show how well the treatment controlled the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69000, France
-
Hôpital Cochin
Paris, 75014, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut de Cancérologie de l'Ouest - Site René Gauducheau
Nantes, 44805, France
Conditions
Explore the condition pages connected to this study.